Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment

TY - JOUR

T1 - Beyond the jab

T2 - A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment

AU - Naniche, Denise

AU - Hotez, Peter

AU - Bottazzi, Maria Elena

AU - Ergonul, Onder

AU - Figueroa, J. Peter

AU - Gilbert, Sarah

AU - Gursel, Mayda

AU - Hassanain, Mazen

AU - Kang, Gagandeep

AU - Kaslow, David

AU - Kim, Jerome H.

AU - Lall, Bhavna

AU - Larson, Heidi

AU - Sheahan, Timothy

AU - Shoham, Shmuel

AU - Wilder-Smith, Annelies

AU - Sow, Samba O.

AU - Strub-Wourgaft, Nathalie

AU - Yadav, Prashant

AU - Batista, Carolina

N1 - Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK) since March 2020. SG is cofounder of Vaccitech and has a patent on ChAdOx1 nCoV-19 licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JPF and GK are members of the WHO SAGE Working Group on COVID-19 vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). DK reports grants from Bill and Melinda Gates Foundation (BMGF) and grants from CEPI. JK reports personal fees from SK biosciences. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline, and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, and Celltrion, outside the submitted work. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. Funding Information: DN wrote the first draft of the manuscript. PH, MEB, and BL managed the process of review. All authors contributed equally and provided critical feedback, reference sources, and critical revisions for intellectual content and verified the information presented here. *Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force:, Peter Hotez (Co-Chair), Maria Elena Bottazzi (Co-Chair), Carolina Batista, Onder Ergonul, J. Peter Figueroa, Sarah Gilbert, Mayda Gursel, Mazen Hassanain, Gagandeep Kang, David Kaslow, Jerome H. Kim, Bhavna Lall (Assistant to Co-Chairs), Heidi Larson, Denise Naniche, Timothy Sheahan, Shmuel Shoham, Annelies Wilder-Smith, Samba O. Sow, Nathalie Strub-Wourgaft, Prashant Yadav. We thank Jeffrey Sachs, Chair of the Lancet COVID-19 Commission, and Yanis Ben Amor, member of the Secretariat of this Commission, for their invaluable review and feedback.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85107853395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107853395&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2021.100925

DO - 10.1016/j.eclinm.2021.100925

M3 - Comment/debate

C2 - 34099998

AN - SCOPUS:85107853395

SN - 2589-5370

VL - 36

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 100925

ER -